Malignant Glioma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Malignant Glioma – Drugs In Development, 2023’, provides an overview of the Malignant Glioma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Glioma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Malignant Glioma
- The report reviews pipeline therapeutics for Malignant Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Malignant Glioma therapeutics and enlists all their major and minor projects
- The report assesses Malignant Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Malignant Glioma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Malignant Glioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Alaunos Therapeutics IncAstraZeneca Plc
Beijing Inno Medicine Co Ltd
Beijing Neoantigen Biotechnology Co Ltd
Bexion Pharmaceuticals Inc
Bionaut Labs Inc
Bristol-Myers Squibb Co
Candel Therapeutics Inc
Celularity Inc
CHA Biotech Co Ltd
Chimeric Therapeutics Ltd
China Medical University
City of Hope
Day One Biopharmaceuticals Inc
Duet Therapeutics Inc
Duke University
FUDA Cancer Hospital
Fuzhou Tcelltech Biological Science and Technology Inc
Gan & Lee Pharmaceuticals Co Ltd
Gibson Oncology LLC
Gilead Sciences Inc
Guangzhou Virotech Pharmaceutical Co Ltd
Hebei Senlang Biotechnology Co Ltd
Immix BioPharma Inc
Immunomic Therapeutics Inc
Immvira Co Ltd
Imvax Inc
Istari Oncology Inc
Jikei University School of Medicine
Keio University
Kidswell Bio Corp
Komipharm International Co Ltd
Laminar Pharmaceuticals SA
Lisata Therapeutics Inc
Moleculin Biotech Inc
NanoPharmaceuticals LLC
Nationwide Children's Hospital
Neonc Technologies Inc
Norwegian University of Science and Technology
Novartis AG
Oblato Inc
Ohio State University
OncoTherapy Science Inc
Orphelia Pharma SAS
Osaka University
PharmAbcine Inc
Philogen SpA
Pyramid Biosciences Inc
Rockefeller University
Royal Wuxi Biological Pharmaceutical Co Ltd
Simcere Pharmaceutical Group Ltd
Smerud Medical Research International AS
Starlight Therapeutics Inc
Stemline Therapeutics Inc
Sumitomo Pharma Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Tactical Therapeutics Inc
Targepeutics Inc
UCLAs Jonsson Comprehensive Cancer Center
Universita Degli Studi Gd Annunzio Chieti Pescara
University Hospital Basel
Wayshine Biopharma Inc
Xiangxue Pharmaceutical Co Ltd